Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Genmab

Why Is Genmab Stock Trading Lower On Monday?

On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endometrial cancer.

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S (NASDAQ:GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Should You Be Investing in Nordic Companies?

Should you be Investing in Nordic companies? This corner of Europe presents unique opportunities for investors.

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Where Genmab Stands With Analysts

Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Genmab

Analyst Ratings for Genmab

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

Evercore ISI Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Endometrial Cancer

Places

359,085 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play